Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 1-2, 2010, Pages 164-170

  Rauvala, Heikki ^a   Rouhiainen, Ari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Amphoterin; Cell migration; HMGB1; Proteoglycan; RAGE; Toll like receptors

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; CD24 ANTIGEN; CELL SURFACE RECEPTOR; CYTOKINE; DNA; GLYCOLIPID; HIGH MOBILITY GROUP B1 PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; PROTEIN CDC42; PROTEOGLYCAN; REACTIVE OXYGEN METABOLITE; THROMBOMODULIN; THROMBOPLASTIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1;

BINDING SITE; CELL MIGRATION; CELL MOTILITY; CHROMATIN STRUCTURE; DISSEMINATED INTRAVASCULAR CLOTTING; DNA BINDING; DOWN REGULATION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STROKE; TISSUE INJURY; TRANSCRIPTION REGULATION;

ANIMALS; CELL MOVEMENT; DISEASE; HMGB1 PROTEIN; HUMANS; INFLAMMATION; PROTEOGLYCANS; RECEPTORS, CELL SURFACE;

EID: 74549177554     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2009.11.012     Document Type: Review

References (87)

1. Hock R., Furusawa T., Ueda T., and Bustin M. HMG chromosomal proteins in health and disease. Trends Cell Biol 17 (2007) 72-79
2. Goodwin G.H., and Johns E.W. Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids. Eur. J. Biochem. 40 (1973) 215-219
3. Rauvala H., and Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J. Biol. Chem. 262 (1987) 16625-16635
4. Rauvala H., Merenmies J., Pihlaskari R., Korkolainen M., Huhtala M.-L., and Panula P. The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J. Cell Biol. 107 (1988) 2293-2305
5. Bianchi M.E., Beltrame M., and Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 243 (1989) 1056-1059
6. Merenmies J., Pihlaskari R., Laitinen J., Wartiovaara J., and Rauvala H. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J. Biol. Chem 266 (1991) 16722-16729
7. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins, Trends Biochem. Sci. 26 (2001) 152-153
8. Schmidt A.M., Vianna M., Gerlach M., Brett R.J., Kao J., Esposito C., Hegarty H., Hurley W., and Clauss M. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267 (1992) 14987-14997
9. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The biology of the receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498 (2000) 99-111
10. Bustin M., and Neihart N.K. Antibodies against chromosomal HMG proteins stain the cytoplasm of mammalian cells. Cell 16 (1979) 181-189
11. Parkkinen J., Raulo E., Merenmies J., Nolo R., Kajander E.O., Baumann M., and Rauvala H. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation, J. Biol. Chem. 268 (1993) 19726-19738
12. Lotze M.T., and Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5 (2005) 331-342
13. Muller S., Ronfani L., and Bianchi M.E. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J. Intern. Med. 255 (2004) 332-343
14. Ulloa L., and Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17 (2006) 189-201
15. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., Molina P.E., Abumrad N.N., Sama A., and Tracey K.J. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
16. Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., Rauvala H., Herman G., Tracey K.J., Lee M.L., Andersson J., Tokics L., and Treutiger C.J. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit. Care Med. 33 (2005) 564-573
17. Rouhiainen A., Kuja-Panula J., Wilkman E., Pakkanen J., Stenfors J., Tuominen R.K., Lepantalo M., Carpen O., Parkkinen J., and Rauvala H. Regulation of monocyte migration by amphoterin (HMGB1). Blood 104 (2004) 1174-1182
18. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., and Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22 (2003) 5551-5560
19. Youn J.H., and Shin J.S. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177 (2006) 7889-7897
20. Ito I., Fukuzawa J., and Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J. Biol. Chem. 282 (2007) 16336-16344
21. Ditsworth D., Zong W.X., and Thompson C.B. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J. Biol. Chem. 282 (2007) 17845-17854
22. Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., and Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62 (2002) 4805-4811
23. Sparatore B., Patrone M., Passalacqua M., Pedrazzi M., Gaggero D., Pontremoli S., and Melloni E. Extracellular processing of amphoterin generates a peptide active on erythroleukaemia cell differentiation. Biochem. J. 357 (2001) 569-574
24. Kallijarvi J., Haltia M., and Baumann M.H. Amphoterin includes a sequence motif which is homologous to the Alzheimer's β-amyloid peptide (Aβ), forms amyloid fibrils in vitro, and binds avidly to Aβ. Biochemistry 40 (2001) 10032-10037
25. Cardin A.D., and Weintraub H.J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9 (1989) 21-32
26. Huttunen H.J., and Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Int. Med. 255 (2004) 351-366
27. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., Morser J., Stern D., and Schmidt A.M. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 270 (1995) 25752-25761
28. Huttunen H.J., Fages C., and Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 274 (1999) 19919-19924
29. Hudson B.I., Kalea A.Z., Del Mar Arriero M., Harja E., Boulanger E., D'Agati V., and Schmidt A.M. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem 283 (2008) 34457-34468
30. Wallar B.J., and Alberts A.S. The formins: active scaffolds that remodel the cytoskeleton. Trends Cell Biol 13 (2003) 435-446
31. Chavakis T., Bierhaus A., Al-Fakhri N., Schneider D., Witte S., Linn T., Nagashima M., Morser J., Arnold B., Preissner K.T., and Nawroth P.P. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198 (2003) 1507-1515
32. Chavakis E., Hain A., Vinci M., Carmona G., Bianchi M.E., Vajkoczy P., Zeiher A.M., Chavakis T., and Dimmeler S. High-mobility group nox 1 activates integrin-dependent homing of endothelial progenitor cells. Circ. Res. 100 (2007) 204-212
33. Orlova V.V., Choi E.Y., Xie C., Chavakis E., Bierhaus A., Ihanus E., Ballantyne C.M., Gahmberg C.G., Bianchi M.E., Nawroth P.P., and Chavakis T. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26 (2007) 1129-1139
34. Kuja-Panula J., Kiiltomäki M., Yamashiro T., Rouhiainen A., and Rauvala H. AMIGO, a transmembrane protein implicated in axon tract development, defines a novel protein family with leucine-rich repeats. J. Cell. Biol. 160 (2003) 963-973
35. Rong L.L., Trojaborg W., Qu W., Kostov K., Yan S.D., Gooch C., Szabolcs M., Hays A.P., and Schmidt A.M. Antagonism of RAGE suppresses peripheral nerve regeneration. FASEB J 18 (2004) 1812-1817
36. Rong L.L., Yan S.F., Wendt T., Hans D., Pachydaki S., Bucciarelli L.G., Adebayo A., Qu W., Lu Y., Kostov K., Lalla E., Yan S.D., Gooch C., Szabolcs M., Trojaborg W., Hays A.P., and Schmidt A.M. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J. 18 (2004) 1818-1825
37. Taguchi A., Blood D.C., Del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., and Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405 (2000) 354-360
38. Fages C., Nolo R., Huttunen H.J., Eskelinen E.-L., and Rauvala H. Regulation of cell migration by amphoterin. J. Cell Sci. 113 (2000) 611-620
39. Schlueter C., Weber H., Meyer B., Rogalla P., Roser K., Hauke S., and Bullerdiek J. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am. J. Pathol. 166 (2005) 1259-1263
40. van Beijnum J.R., Dings R.P., van der Linden E., Zwaans B.M.M., Ramaekers F.C.S., Mayo K.H., and Griffioen A.W. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108 (2006) 2339-2348
41. Dumitriu I.E., Baruah P., Manfredi A.A., Bianchi M.E., and Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol 26 (2005) 381-387
42. Dumitriu I.E., Bianchi M.E., Bacci M., Manfredi A.A., and Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81 (2007) 84-91
43. Yang D., Chen Q., Yang H., Tracey K.J., Bustin M., and Oppenheim J.J. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukoc. Biol. 81 (2007) 59-66
44. Porto A., Palumbo R., Pieroni M., Aprigliano G., Chiesa R., Sanvito F., Maseri A., and Bianchi M.E. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 20 (2006) 2565-2566
45. Palumbo R., Sampaolesi M., De Marchis F., Tonlorenzi R., Colombetti S., Mondino A., Cossu G., and Bianchi M.E. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 164 (2004) 441-449
46. Limana F., Germani A., Zacheo A., Kajstura J., Di Carlo A., Borsellino G., Leoni O., Palumbo R., Battistini L., Rastaldo R., Muller S., Pompilio G., Anversa P., Bianchi M.E., and Capogrossi M.C. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ. Res. 97 (2005) e73-83
47. Germani A., Limana F., and Capogrossi M.C. Pivotal advances: high-mobility group box 1 protein-a cytokine with a role in cardiac repair. J. Leukoc. Biol. 81 (2007) 41-45
48. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., Susarla S.M., Ulloa L., Wang H., DiRaimo R., Czura C.J., Wang H., Roth J., Warren H.S., Fink M.P., Fenton M.J., Andersson U., and Tracey K.J. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101 (2004) 296-301
49. Yang R., Harada T., Mollen K.P., Prince J.M., Levy R.M., Englert J.A., Gallowitsch-Puerta M., Yang L., Yang H., Tracey K.J., Harbrecht B.G., Billiar T.R., and Fink M.P. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol. Med. 12 (2006) 105-114
50. Raman K.G., Sappington P.L., Yang R., Levy R.M., Prince J.M., Liu S., Watkins S.K., Schmidt A.M., Billiar T.R., and Fink M.P. The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006) G556-G565
51. Liliensiek B., Weigand M.A., Bierhaus A., Nicklas W., Kasper M., Hofer S., Plachky J., Grone H.J., Kurschus F.C., Schmidt A.M., Yan S.D., Martin E., Schleicher E., Stern D.M., Hammerling G.G., Nawroth P.P., and Arnold B. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113 (2004) 1641-1650
52. Fan J., Li Y., Levy R.M., Fan J.J., Hackam D.J., Vodovotz Y., Yang H., Tracey K.J., Billiar T.R., and Wilson M.A. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J. Immunol. 178 (2007) 6573-6580
53. Tsung A., Zheng N., Jeyabalan G., Izuishi K., Klune J.R., Geller D.A., Lotze M.T., Lu L., and Billiar T.R. Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J. Leukoc. Biol. 81 (2007) 119-128
54. Hatada T., Wada H., Nobori T., Okabayashi K., Maruyama K., Abe Y., Uemoto S., Yamada S., and Maruyama I. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb. Haemost. 94 (2005) 975-979
55. Ito T., Kawahara K., Nakamura T., Yamada S., Nakamura T., Abeyama K., Hashiguchi T., and Maruyama I. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J. Thromb. Haemost. 5 (2007) 109-116
56. Rouhiainen A., Imai S., Rauvala H., and Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 84 (2000) 1087-1094
57. Kim J.B., Lim C.M., Yu Y.M., and Lee J.K. Induction and subcellular localization of high-mobility group box-1 (HMGB1) in the postischemic rat brain. J. Neurosci. Res. 86 (2008) 1125-1131
58. Kim J.B., Sig Choi J., Yu Y.M., Nam K., Piao C.S., Kim S.W., Lee M.H., Han P.L., Park J.S., and Lee J.K. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J. Neurosci. 26 (2006) 6413-6421
59. Liu K., Mori S., Takahashi H.K., Tomono Y., Wake H., Kanke T., Sato Y., Hiraga N., Adachi N., Yoshino T., and Nishibori M. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J. 21 (2007) 3904-3939
60. Pedrazzi M., Raiteri L., Bonanno G., Patrone M., Ledda S., Passalacqua M., Milanese M., Melloni E., Raiteri M., Pontremoli S., and Sparatore B. Stimulation of excitatory amino acid release from adult mouse brain glia subcellular particles by high mobility group box 1 protein. J. Neurochem. 99 (2006) 827-838
61. Muhammad S., Barakat W., Stoyanov S., Murikinati S., Yang H., Tracey K.J., Bendszus M., Rossetti G., Nawroth P.P., Bierhaus A., and Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 28 (2008) 12023-12031
62. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M., Nawroth P.P., and Understanding R. the receptor for advanced glycation end products. J. Mol. Med 83 (2005) 876-886
63. Wautier J.L., and Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 95 (2004) 233-238
64. Naka Y., Bucciarelli L.G., Wendt T., Lee L.K., Rong L.L., Ramasamy R., Yan S.F., Schmidt A.M., and axis R. Animal models and novel insights into the vascular complications of diabetes. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1342-1349
65. Kalinina N., Agrotis A., Antropova Y., DiVitto G., Kanellakis P., Kostolias G., Ilyinskaya O., Tararak E., and Bobik A. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2320-2325
66. Inoue K., Kawahara K.-I., Biswas K.K., Ando K., Mitsudo K., Nobuyoshi M., and Maruyama I. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc. Pathol. 16 (2007) 136-143
67. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., and Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279 (2004) 7370-7377
68. Rouhiainen A., Tumova S., Valmu L., Kalkkinen N., and Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J. Leukoc. Biol. 81 (2007) 49-58
69. Tian J., Avalos A.M., Mao S.Y., Chen B., Senthil K., Wu H., Parroche P., Drabic S., Golenbock D., Sirois C., Hua J., An L.L., Audoly L., La Rosa G., Bierhaus A., Naworth P., Marshak-Rothstein A., Crow M.K., Fitzgerald K.A., Latz E., Kiener P.A., and Coyle A.J. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8 (2007) 487-496
70. Sha Y., Zmijewski J., Xu Z., and Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J. Immunol. 180 (2008) 2531-2537
71. Urbonaviciute V., Fürnrohr B.G., Meister S., Munoz L., Heyder P., De Marchis F., Bianchi M.E., Kirschning C., Wagner H., Manfredi A.A., Kalden J.R., Schett G., Rovere-Querini P., Herrmann M., and Voll R.E. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205 (2008) 3007-3018
72. Salmivirta M., Rauvala H., Elenius K., and Jalkanen M. Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Exp. Cell. Res. 200 (1992) 444-451
73. Rauvala H., Huttunen H.J., Fages C., Kaksonen M., Kinnunen T., Imai S., Raulo E., and Kilpeläinen I. Heparin-binding proteins HB-GAM (Pleiotrophin) and amphoterin in the regulation of cell motility. Matrix Biol. 19 (2000) 377-387
74. Hienola A., Tumova S., Kulesskiy E., and Rauvala H. N-Syndecan deficiency impairs neural migration in brain. J. Cell Biol. 174 (2006) 569-580
75. Milev, Chiba A., Häring M., Rauvala H., Schachner M., Ranscht B., Margolis R.K., and Margolis R.U. High affinity binding and overlapping localization of neurocan and phosphacan/protein-tyrosine phosphatase theta/beta with tenascin-R, amphoterin, and the heparin-binding growth-associated molecule. J. Biol. Chem. 273 (1998) 6998-7005
76. Maeda N., and Noda M. Involvement of receptor-like protein tyrosine phosphatase zeta/RPTPbeta and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J. Cell Biol. 142 (1998) 203-216
77. Rauvala H. An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J 8 (1989) 2933-2941
78. Li Y.-S., Milner P.G., Chauhan A.K., Watson M.A., Hoffman R.M., Kodner C.M., Milbrandt J., and Deuel T.F. Cloning and expression of a developmentally regulated protein that enhances mitogenic and neurite outgrowth activity. Science 250 (1990) 1690-1694
79. Liu G., Wang J., Park Y.J., Tsuruta Y., Lorne E.F., Zhao X., and Abraham E. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J. Immunol. 181 (2008) 4240-4246
80. Mohan P.S., Laitinen J., Merenmies J., Rauvala H., and Jungalwala F.B. Sulfoglycolipids bind to adhesive protein amphoterin (p30) in the nervous system. Biochem. Biophys. Res. Commun. 182 (1992) 689-696
81. Kleene R., and Schachner M. Glycans and neural cell interactions. Nat. Rev. Neurosci. 5 (2004) 195-208
82. Chou D.K., Evans J.E., and Jungalwala F.B. Identity of nuclear high-mobility-group protein, HMG-1, and sulfoglucuronyl carbohydrate-binding protein, SBP-1, in brain. J. Neurochem. 77 (2001) 120-131
83. Chou D.K., Zhang J., Smith F.I., McCaffery P., and Jungalwala F.B. Developmental expression of receptor for advanced glycation end products (RAGE), amphoterin and sulfoglucuronyl (HNK-1) carbohydrate in mouse cerebellum and their role in neurite outgrowth and cell migration. J. Neurochem. 90 (2004) 1389-1401
84. Koutsi A., Papapanagiotou A., and Papavassiliou A.G. Thrombomodulin: from haemostasis to inflammation and tumourigenesis. Int. J. Biochem. Cell Biol. 40 (2008) 1669-1673
85. Van de Wouwer M., and Conway E.M. Novel functions of thrombomodulin in inflammation. Crit. Care Med. 32 (2004) S254-261
86. Abeyama K., Stern D.M., Ito Y., Kawahara K., Yoshimoto Y., Tanaka M., Uchimura T., Ida N., Yamazaki Y., Yamada S., Yamamoto Y., Yamamoto H., Iino S., Taniguchi N., and Maruyama I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115 (2005) 1267-1274
87. Chen G.Y., Tang J., Zheng P., and Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 323 (2009) 1722-1725